Skip to main content

Table 2 Summary of studies reporting assessment of KRAS molecular marker

From: Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review

Reference

Patient demographics:

Description of matched pairs

Synchronous/metachronous/metastases, n:n

Molecular marker assessment technique

Mutation frequency,c n/N (%)

Concordance, n/N (%)

(i) Median age (range), years

N

Tumour sample storage form

Primary

Metastatic: n

 

(ii) Gender, n/N (%) male

Histological subtype: n

Time between primary and metastatic tumour sample collection b

(iii) Ethnicity [countrya]

 

(iv) Smoking status, n/N (%)

Assessment of KRAS molecular marker

 Alsdorf et al. [55]

(i) N/A

19

FFPE

Lung

Lymph node

N/A

ARMS method with direct sequencing after enrichment of tumour cells by laser capture microdissection

19/19 (100) vs 19/19 (100)

19/19 (100)

(ii) N/A

N/A

(iii) [Germany]

(iv) N/A

 Badalian et al. [57]

(i) N/A (47–76)

11

FFPE

Lung

Bone

N/A

RFLP-PCR

3/11 (27) vs 3/11 (27)

7/11 (64)

(ii) 8/11 (72.7)

N/A

(iii) [Hungary]

(iv) N/A

 Cortot et al. [3]

(i) [Mean] 59.7 (39–73)

21

FFPE

Lung

Brain: 13

6:15

Direct sequencing and mutant-enriched PCR

[Direct sequencing]

[Direct sequencing]

(ii) 6/21 (28.6)

ADC: 16

Lung: 4

N/A

3/21 (14) vs 4/21 (19)

15/21 (71)

(iii) [France]

SSC: 2

Bone: 2

[Mutant-enriched PCR]

(iv) N/A

LCC: 2

Soft tissue: 2

17/21 (81)

 Holst et al. [58]

(i) [Mean] 55.7 (2–72)

10

N/A

Lung

Synchronous/metachronous intrathoracic metastases

Numbers not specified

Topographic genotyping and direct sequencing

6/10 (60) vs 6/10 (60)

10/10 (100)

(ii) Male:female ratio, 1:1

 

N/A

(iii) [USA]

(iv) 70 % of patients had a positive smoking history

 Li et al. [56]

(i) 60 (36–80)

15

FFPE

Lung

Various

N/A

Oligodeoxy-nucleotide hybridisation of DNA amplified by PCR

5/15 (33) vs 5/15 (33) [present in multiple metastatic sites]

15/15 (100)

(ii) 13/15 (87)

ADC: 6

[Concurrent]

(iii) [Spain]

SSC: 4

(iv) Never-smoker: 1/15 (7); ever-smoker: 14/15 (93)

SCC: 3

LCC: 2

  1. ADC Adenocarcinoma, ARMS Amplification‐refractory mutation system, DNA Deoxyribonucleic acid, FFPE Formalin-fixed paraffin-embedded, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma, N/A Not available, PCR Polymerase chain reaction, RFLP-PCR Restriction fragment length polymorphism-polymerase chain reaction, SSC Squamous cell carcinoma
  2. aAs described in study (country from which samples were taken from)
  3. bConcurrent or non-concurrent if time not specified
  4. cPrimary vs metastatic tumour samples